Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

This newsletter is taking a summer break next week but will return to your inbox the following Monday. Enjoy your July 4 ...

Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

As fired and retired scientists rallied outside in the Atlanta heat, an advisory panel that Robert F. Kennedy Jr. handpicked ...

On April 8, when stocks were on the verge of plunging into a bear market, few Wall Street experts were predicting that the ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A startling new vision of vaccination in America is becoming clearer — one likely to involve fresh scrutiny of established ...

MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new preventive shot against ...